Can chronic inflammatory signaling disrupt insulin-receptor pathways and increase compensatory insulin output?

Chronic, low-grade inflammation commonly accompanies obesity, fatty liver disease, and insulin resistance. The claim is biologically credible, with the most direct human evidence showing inflammatory cytokines can impair insulin signaling in muscle and adipocytes; hepatic evidence is mainly associative.

Tissue-specific insulin-signaling effects

• Muscle: Human TNF-α infusion reduced insulin-stimulated glucose disposal, largely attributable to skeletal muscle. It increased inhibitory IRS-1 serine phosphorylation, reduced IRS-1 tyrosine phosphorylation, and suppressed downstream Akt/AS160 signaling—an experimentally coherent mechanism for impaired glucose uptake.
• Adipose tissue: In human adipocytes, IL-6 reduced insulin-stimulated IRS-1 tyrosine phosphorylation and glucose uptake. Chronic cytokine signaling is consistent with JAK–STAT/SOCS3 inhibition of the IRS–PI3K–Akt pathway, although the in-vivo magnitude in human fat remains less certain.
• Liver: In NAFLD, clamp studies show impaired insulin-mediated suppression of endogenous glucose production and reduced hepatic insulin-receptor/Akt signaling. In chronic hepatitis C, hepatic IL-18 and SOCS3 correlate with impaired hepatic insulin action. These data support plausibility, but liver disease, adiposity, and metabolic injury may underlie both inflammation and insulin resistance.

Insulin output and clinical interpretation

• Acute human endotoxemia produces inflammatory activation and approximately 35% lower insulin sensitivity, with studies reporting increased acute insulin secretion without demonstrable beta-cell dysfunction. This supports short-term compensation for reduced insulin action.
• It does not establish that chronic inflammation independently causes persistent hyperinsulinemia: hs-CRP did not clearly predict worsening insulin secretion after accounting for insulin sensitivity in METSIM, and CRP–fasting-insulin associations attenuated with waist circumference adjustment.
• Circulating insulin alone cannot distinguish increased pancreatic secretion from reduced hepatic insulin clearance; C-peptide-based measures are needed.

Bottom line

• Chronic inflammatory signaling is a plausible contributor to insulin resistance across liver, muscle, and fat, strongest mechanistically in muscle. Compensatory insulin output is credible during inflammatory insulin resistance, but a sustained, inflammation-driven increase independent of adiposity is not established.